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Abstract 
Plasmodium vivax has been largely neglected over the past century, despite a widespread recognition of its burden 
across region where it is endemic. The parasite invades reticulocytes, employing the interaction between Plasmo-
dium vivax Duffy binding protein (PvDBP) and human Duffy antigen receptor for chemokines (DARC). However, P. 
vivax has now been observed in Duffy‑negative individuals, presenting a potentially serious public health problem 
as the majority of African populations are Duffy‑negative. Invasion of Duffy‑negative reticulocytes is suggested to be 
through duplication of the PvDBP and a novel protein encoded by P. vivax erythrocyte binding protein (EBP) genes. 
The emergence and spread of specific P. vivax strains with ability to invade Duffy‑negative reticulocytes has, therefore, 
drawn substantial attention and further complicated the epidemiology and public health implication of vivax malaria. 
Given the right environment and vectorial capacity for transmission coupled with the parasite’s ability to invade Duffy‑
negative individuals, P. vivax could increase its epidemiological significance in Africa. In this review, authors present 
accruing knowledge on the paradigm shift in P. vivax invasion of Duffy‑negative reticulocytes against the established 
mechanism of invading only Duffy‑positive individuals and offer a perspective on the epidemiological diagnostic and 
public health implication in Africa.
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Background
Malaria affects one-third of the world’s population and 
kills hundreds of thousands across the globe [1]. Plas-
modium vivax is the most widespread species of human 
malaria and more than 3 billion people live in P. vivax-
endemic regions [2]. Unlike Plasmodium falciparum, P. 
vivax was believed not to be a major health problem in 
Africa. However, until recently, P. vivax infections have 
been widely reported in several African countries and 
its emergence is not surprising given the presence of a 
suitable environment, competent vectors and suscepti-
ble human hosts [3]. Plasmodium vivax not only differs 
from P. falciparum in terms of its epidemiology, but also 
its biology and evolutionary trajectory. These unique fea-
tures enable P. vivax to survive under a wide range of cli-
matic and ecological settings with the abilities to adapt 
to both temperate and tropical climates. Other features, 
including P. vivax ability to form hypnozoites, a stage of 
which the parasite can remain quiescent from months 
to years [4], an invasion preference of reticulocytes that 
only make up a small proportion of circulating erythro-
cytes, the absence of in vitro cultures, and rapidly form-
ing gametocytes all together make elimination of vivax 
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The epidemiology of P. vivax in Africa remains poorly 
understood, although P. vivax transmission from almost 
all countries across the continent has been reported from 
various entomological, serological, community preva-
lence surveys, including clinical infection data from local 
residents and travellers returning to malaria-free coun-
tries [6]. These reports have provided substantive evi-
dence that P. vivax transmission is ongoing throughout 
Africa [3, 7]. However, there is still a paucity of data on 
the contemporary distribution of P. vivax in the region. 
There are increasing reports of P. vivax infections in 
Duffy-negative populations of Africa [8] as determined 
by different diagnostic tools. Indeed, P. vivax has been 
observed to be less severe in Duffy-negative Africans 
compared to their Duffy-positive counterparts [9]. This 
may be underpinned by the fact that P. vivax is poorly 
adapted to Duffy-negative individuals and may change as 
the parasite evolves to optimize its ability to infect Duffy-
negative populations.
Here, authors review the contemporary biology and 
epidemiology of P. vivax among the spectrum of Duffy 
phenotype populations across Africa and synthesize data 
accrued on the invasion mechanisms of Duffy-negative 
erythrocytes and novel parasite ligands and host recep-
tors that enable the parasites to invade reticulocytes. To 
achieve this, published articles was searched in the fol-
lowing electronic databases: Google Scholar, (www.googl 
e.schol ar.com) and PubMed (www.pubme d.gov). Search 
terms included Plasmodium vivax, Duffy OR CD234 OR 
DARC, parasite ligands, host receptors, molecular epide-
miology, invasion, mechanism. No restriction on year of 
publication was imposed but only articles published in 
English were considered.
Studies were selected if they met the following criteria: 
(1) The study involved human participants; (2) infections 
analysed were either P. falciparum and P. vivax co-infec-
tions or pure P. vivax infections; and, (3) studies were 
conducted in African or South American populations. 
Selected studies were entered into Mendeley Reference 
Manager and the following information was recorded: (1) 
country where study was conducted; (2) the case preva-
lence of P. vivax reported; (3) Duffy phenotypes reported; 
(4) comments on disease pathogenesis, particularly for 
Duffy-negative infections; (5) proposed mechanisms 
of infections of Duffy-negative individuals; (6) novel 
receptor–ligand interactions reported; and, (7) study 
conclusions.
Diagnostic challenges associated with Plasmodium vivax 
infections
Plasmodium vivax infections persist with low levels of 
parasitaemia either as mono-infections or co-infections 
with P. falciparum in co-endemic settings, making it 
relatively difficult to diagnose with microscopy, which 
is the gold standard for malaria detection [10]. In most 
parts of Africa, particularly in Duffy-negative popu-
lations, malaria rapid diagnostic test kits (RDTs) are 
mainly aimed at detecting P. falciparum and sometimes 
minor species, such as Plasmodium ovale and Plasmo-
dium malariae, but not specifically P. vivax, despite the 
increasing number of P. vivax reported across Africa and 
in Duffy-negative individuals. Therefore, P. vivax infec-
tions are often misdiagnosed either by mistake or because 
parasitaemia is too low given that its P. vivax invades 
reticulocytes that comprise only a small fraction of the 
circulating erythrocytes [5]. Owing to the increased 
ability to deploy molecular detection platforms, such 
as polymerase chain reaction (PCR), countries that had 
hitherto not reported any P. vivax infections are begin-
ning to report increasing numbers of these infections in 
community surveys [11]. This is apparent that infections 
can be easily missed by the conventional microscopy 
and/or RDTs in such community-based surveillance [9, 
12] and, therefore, hamper an accurate assessment of P. 
vivax prevalence in endemic areas across Africa. More-
over, with the advent of whole genome sequencing of 
Plasmodium spp, genome analysis of P. vivax from clini-
cal sources will uncover the true magnitude of infections 
among Duffy-positive/negative populations [13].
Evolutionary and clinical significance of Plasmodium vivax 
in Duffy‑negatives
For many years epidemiologist thought that Duffy-neg-
ative individuals were totally resistant to vivax malaria 
and the complete resistance of Duffy-negatives to vivax 
malaria was the most striking example of association of 
a genetic trait with an infectious disease [14]. On the 
contrary, recent studies have demonstrated the capac-
ity of P. vivax to infect human erythrocytes with or 
without the Duffy antigen to cause blood-stage infec-
tions [12, 15, 16]. A longitudinal study conducted in 
Mali by Niangaly et al. [17], found 2% asymptomatic P. 
vivax infections in Duffy-negative anaemic children. In 
another study conducted in Cameroon by Russo et  al. 
[18], 27 P. vivax-infected Duffy-negative patients pre-
sented with fever. In admixture populations, according 
to Menard et  al. [15], Duffy-positive individuals may 
serve as a reservoir of P. vivax, providing an opportu-
nity for this parasite to infect hepatocytes of Duffy-
negative people with the selection of novel P. vivax 
strains with the ability to invade Duffy-negative eryth-
rocytes. Taken together, these data suggest a paradigm 
shift in the understanding of P. vivax invasion biology 
and raises more questions than answers. Could the 
adaptation of vivax to infect Duffy-negative individu-
als be frequency dependent? If so, what ratio of Duffy 
Page 3 of 10Golassa et al. Malar J          (2020) 19:299  
phenotypes fuel vivax adaptation to invade Duffy-nega-
tives? There is yet limited evidence which supports the 
inability of vivax to spread to populations such as those 
in West Africa where the Duffy-negative allele is fixed. 
At any rate, given that P. vivax can cause both clinical 
and sub-clinical infections in Duffy-negative patients, 
these evolutionary realities are of public health con-
cern, particularly when major investments in interven-
tions against P. falciparum are driving falciparum to 
elimination but creating a niche for other Plasmodium 
spp.
Epidemiology, disease severity and public health 
importance
While P. falciparum is considered the deadliest malaria 
parasite with most severe clinical outcomes, P. vivax is 
more widespread and often associated with high levels 
of morbidity. The overall burden, economic impact and 
severity associated with vivax malaria has been underes-
timated until some recent studies showing the associa-
tion of P. vivax infections with severe malaria and death 
[19]. The clinical spectrum of P. vivax-associated malaria 
ranges from asymptomatic parasitaemia and uncom-
plicated febrile illness to severe and fatal malaria. Other 
severe clinical manifestations include multi-organ dys-
function with anaemia and thrombocytopaenia [20]. 
Another major public health concern of P. vivax is its 
association with spontaneous abortions, premature and 
low birth weight in pregnant women. These clinical fea-
tures have mostly been described for Duffy-positive pop-
ulations and may vary among Duffy-negative individuals 
in Africa. In areas where P. falciparum and P. vivax co-
exist, while the total malaria burden decreases, the pro-
portion of cases attributable to P. vivax increases [21].
In P. vivax, gametocytes appear simultaneously with 
the asexual schizonts [22] while in P. falciparum, game-
tocytes usually appear 10–14  days after infection. Such 
a difference in development not only increases the 
length of time the individual remains infectious, but 
also increases the likelihood of transmission before the 
infected individual seeks treatment [23]. Moreover, P. 
vivax ability to relapse from dormant liver-stage hypno-
zoites, from weeks to years after clearance of the primary 
blood-stage infection is a major obstacle to its control 
and elimination [24]. The increased population at risk of 
P. vivax infection and the growing clinical burden across 
regions with a spectrum of Duffy phenotypes puts vivax 
malaria on the spotlight as an important public health 
issue [25]. Definitively, Duffy-negative phenotype is not 
a barrier to P. vivax infection and the public health sig-
nificance of vivax malaria should no longer be neglected 
[25].
Plasmodium vivax tropism to reticulocytes and Duffy 
antigens
The sparse distribution of P. vivax in Africa is viewed 
as a consequence of the lack of expression of the Duffy 
antigen on red blood cells (RBCs). Exhibiting distinct red 
cell tropism, malaria parasites use sophisticated inva-
sion mechanisms to identify, penetrate and multiply in 
vector and human host cells. Plasmodium vivax blood-
stage infection is restricted to human reticulocytes, 
whereas P. falciparum can infect all types of RBCs [26]. 
RBC invasion by Plasmodium species requires multiple 
interactions between parasite ligands and host receptors, 
some of which have overlapping and partially redundant 
roles [27]. With the evolutionary arms race between the 
malaria parasites and human hosts, variants of erythro-
cyte receptors and parasites ligands have evolved. In P. 
vivax, the connection between the  PvDBP and DARC 
is a critical pathway, and the only pathway identified so 
far, for P. vivax invasion of human reticulocytes, in spite 
of the increasing reports of P. vivax  infections in Duffy-
negative individuals that rise questions on the specificity 
of Duffy antigens [28, 29]. With increasingly reports of P. 
vivax infection in Duffy-negative populations throughout 
Africa and South America, it is possible that these infec-
tions were historically not detected rather than a recent 
adaptation of certain P. vivax strains.
The invasion of human reticulocytes by  P.  vivax  had 
been known to be completely dependent on the interac-
tion between PvDBP and DARC [30], unlike P.  falcipa-
rum  merozoites that use several erythrocyte receptors 
(e.g., glycophorin A (GPA) and glycophorin C (GPC) 
and ligands (e.g., EBA-175 and EBA-140) for erythrocyte 
invasion. Although DARC is present on the erythrocyte 
surface, P. vivax reticulocyte binding proteins (PvRBPs) 
bind receptors on reticulocytes that are subsequently lost 
during erythrocyte maturation [31]. This enhances the 
exposure of PvDBP binding pocket to young reticulo-
cytes explaining P. vivax tropism [32]. Based on sequence 
homology, the PvRBP family comprises PvRBP1 (com-
posed of PvRBP1a and PvRBP1b) and PvRBP2 (com-
posed of PvRBP2a, PvRBP2b, PvRBP2c) [33]. PvRBP2d 
and PvRBP3 are pseudo-genes that share homology with 
PvRBPs but do not encode functional proteins. Accord-
ing to Miller et  al., Duffy-negative individuals can be 
infected by P. vivax, but are protected from blood-stage P. 
vivax infection [34] indicating that such infections could 
persist as asymptomatic.
DARC polymorphisms and Plasmodium vivax invasion 
canon
DARC is a membrane protein present on the surface of 
erythrocytes and central to P. vivax merozoites invasion 
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of RBCs. Due to its strong geographic differentiation 
and association with vivax malaria resistance, DARC is 
considered as best example to depict positive selection 
in human genome. It belongs to the G protein-coupled 
receptor family (a 35–50  kDa glycoprotein) expressed 
both on the surface of RBCs and endothelial tissue [35]. 
Duffy proteins are also expressed in erythroid precursor 
cells of the bone marrow where P. vivax invasion could be 
occurring to some degree [26]. The Duffy glycoprotein is 
encoded by the FY gene main alleles, FY*A (FY*01) and 
FY*B (FY*02) that are codominantly expressed (Table 1). 
Each allele can be inherited either from mother or father 
and both gene products, Duffy  Fya and  Fyb antigens, 
can be expressed on the RBCs.  Fya and  Fyb differ by a 
single amino acid at position 42 that encodes glycine in 
 Fya and aspartic acid  in  Fyb. Antibodies against  Fya and 
 Fyb (anti-Fya and anti-Fyb) define four main phenotypes: 
Fy(a+b−), Fy(a+b+), Fy(a−b+) and Fy(a−b−). The 
Duffy-negative phenotype, Fy(a−b−), occurs in two-
thirds of African–American Blacks [36] and is associated 
with a single point mutation c.1-67T>C (rs2814778) in 
the GATA-1 binding motif for the erythroid promoter 
of  FY*B   [35] that prevents the expression of  FY*B  in 
RBCs (thus blocks the RBC invasion by  P. vivax), but 
without affecting FY*B expression in other tissues [37, 
38].
The gene encoding the Duffy blood group, Fy, is char-
acterized by a SNP in a GATA-1 transcription factor 
binding site associated with the erythrocyte silent (ES) 
phenotype that has been shown to protect against P. 
Table 1 Variants of the Duffy blood group (ISBY008)
a  Nucleotide numbering within the transcript is numbered according to the major transcript. The GATA-1 mutation listed here as c.-67T>C has been reported 
previously as − 33 and − 46
b  Reference allele FY*02 encodes FY3, FY5, FY6
Phenotype Allele name Nucleotide  changea Exon Predicted amino acid change
FY:1 or Fy(a+) FY*01 or FY*A c.125A>G 2 p.Asp42Gly
FY:2 or Fy(b+)b FY*02 or FY*B
Null phenotypes
 Fy(a−b−) erythroid cells only FY*01N.01 c.‑67T>C Promoter p.0
 Fy(a−b−) FY*01N.02 c.281_295del 2 p.Pro94_Val98del
 Fy(a−b−) FY*01N.03 c.408G>A 2 p.Trp136Ter
 Fy(a−b−) FY*01N.04 c.287G>A 2 p.Trp96Ter
 Fy(a−b−) FY*01N.05 c.327delC 2 p.Phe109Leufs*12
 Fy(a−b−) FY*01N.06 c.395G>A 2 p.Gly132Asp
 Fy(a−b−) FY*01N.07 c.719delG 2 p.Gly240Alafs*4
 Fy(a−b−) erythroid cells only FY*01N.08 c.‑69T>C Promoter p.0
 Fy(a−b−) FY*01N.09 c.296_496delinsAGG CCA CTG 2 p.Leu99_Leu165delins GlnAlaThrAla
 Fy(a−b−) erythroid cells only FY*02N.01 c.‑67T>C Promoter p.0
 Fy(a−b−) FY*02N.02 c.407G>A 2 p.Trp136Ter
 Fy(a−b−) FY*02N.03 c.781G>A 2 p.Gly261Arg
 Fy(a−b−) FY*02N.04 c.179_180delCT 2 p.Ser60Cysfs*16
 Fy(a−b−) FY*02N.05 c.895G>A 2 p.Ala299Thr
 Fy(a−b−) FY*02N.06 c.151delT 2 p.Cys51Alafs*24
Weak phenotypes
 Fy(a+w) FY*01W.01 c.265C>T 2 p.Arg89Cys
 Fy(a+w) FY*01W.02 c.265C>T 2 p.Arg89Cys
c.298G>A p.Ala100Thr
 Fy(a+w) FY*01W.03 c.680G>A 2 p.Gly227Glu
 Fy(b+w), Fyx FY*02W.01 c.265C>T 2 p.Arg89Cys
c.298G>A p.Ala100Thr
 Fy(b+w), Fyx FY*02W.02 c.145G>T 2 p.Ala49Ser
c.265C>T p.Arg89Cys
c.298G>A p.Ala100Thr
 Fy(b+w) FY*02W.03 c.266G>A 2 p.Arg89His
 Fy(b+w) FY*02W.04 c.901C>T 2 p.Pro301Ser
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vivax infection and is at near fixation in sub-Saharan 
Africa and is virtually absent any where else. Indeed, the 
Duffy antigen exhibits extreme geographic differentia-
tion in Africa, but nearly absent from Asia and Europe. 
While ES (Fy*BES allele; FY*02N.01) phenotype impairs 
promoter activity in erythroid cells by disrupting a bind-
ing site for the GATA-1 erythroid transcription factor 
[37] and confers complete protection from vivax malaria, 
low levels of P. vivax infections have been observed in 
Fy*01N.01 homozygotes [39], which indicates that P. 
vivax might be evolving escape-variants able to over-
come the protective effect of Fy*01N.01/FY*01N.01 or 
has evolved a Fy-independent RBC invasion pathway or 
that the GATA-1 SNP does not abolish Fy expression. 
Different allelic forms of the Duffy blood group gene 
could also modify the antigen’s expression level, leading 
to weak phenotype. For example, two variants c.265C>T 
(rs34599082) and c.298G>A (rs13962) of glycoprotein 
Duffy have resulted in weak  Fyb expression [40]. Another 
mutation c.145G>T generating the FY*02W.02 allele has 
also shown to weaken the expression of the  Fyb antigen 
[41, 42]. The expression level of these different weak phe-
notypes needs verification through flow cytometry in 
future studies.
Plasmodium vivax DBP gene duplication 
and Duffy‑negative reticulocyte invasion
Red blood cell invasion by P.  vivax merozoites appears 
to rely heavily on the interaction between PvDBP and 
DARC [43]. Whole-genome sequencing of P. vivax clini-
cal isolates collected from Duffy-negative individuals 
indicates the presence of two and higher copies of the 
PvDBP gene [44]. This observation suggests that the 
PvDBP gene is under strong positive selection [45]. Two 
different types of the duplication have been observed 
among P. vivax clinical isolates from Cambodia [46], 
Ethiopia [44] and Madagascar [47]. Moreover, analysis of 
P. vivax genomes from over 200 isolates originating from 
across the world indicated that copy number variation 
(CNV) at the  PvDBP  locus is one of the most common 
CNVs within the P. vivax genome irrespective of the geo-
graphical origin of the isolates [13]. For instance, in Cam-
bodia, where Duffy-negativity is essentially absent, the 
frequency of PvDBP duplication had reached 40% [13]. 
PvDBP  CNVs seem to be continuously arising  de novo, 
occurring independently within defined geographic 
boundaries based on phylogeographic analysis. Appar-
ently, PvDBP is also evolving rapidly among Duffy-neg-
ative population in most parts of the sub-Saharan Africa, 
presumed to be the origin of P. vivax [48]. In other geo-
graphic areas where almost all individuals are Duffy-pos-
itives, PvDBP duplications have also been observed with 
high frequency [13]. The outcome of this repeated gene 
duplications (or by population size expansion) from the 
ancestral lineage in P. vivax indicates that several sub-
populations are present [49].
CNVs are common in both P. falciparum and P. vivax 
[13]. What initiates PvDBP expansion in P. vivax? For 
example, expansion of mdr1 has been shown to result 
in increased anti-malarial resistance, however, it is 
unlikely that anti-malarial drug pressure plays a role in 
PvDBP  duplication unless the duplication confers an 
increased growth rate to P.  vivax parasites [44]. Owing 
to the critical role that PvDBP-DARC interaction plays 
in  P.  vivax  erythrocyte invasion, it is expected that 
the binding affinity of DARC with high-copies  PvDBP 
could be higher than with single-copy PvDBP para-
sites. However, no association has been found between 
PvDBP  duplications and the efficiency of parasite to 
invade reticulocytes with FY*A or FY*B genotypes [44]. 
Assuming a high adaptability of Plasmodium species, it 
is likely that the duplications emerged in the parasites in 
response to the variation in human Duffy blood group 
across malaria-endemic settings. Recent studies have 
shown that PvDBP gene amplification not only facili-
tates binding to an alternative lower affinity receptor in 
Duffy-negative reticulocytes [16, 44], but also allows P. 
vivax to evade host anti-PvDBP humoral immunity [50], 
reassuring PvDBPII region as a promising candidate for 
a blood-stage vaccine against P. vivax [34]. The polymor-
phic nature of PvDBP certainly allows P. vivax to colo-
nize diverse ecological niches as well as to evade the host 
immune system.
A molecular epidemiology study conducted in Ethio-
pia observed that the proportion of parasites with PvDBP 
amplification was higher in individuals carrying the FY*A 
allele compared to individuals carrying the FY*B [51]. 
On the other hand, in Madagascar where both Duffy-
negative and Duffy-positive individuals coexist, PvDBP 
amplification is not selected in response to the Duffy null 
homozygotes [52]. It is noteworthy to see a higher fre-
quency (56%) of multiple PvEBP copies in Madagascar 
where Duffy-negative and Duffy-positive people coex-
ist than in Cambodia (19%) where mostly Duffy-positive 
people are present [53]. Such a contrast may imply a 
functional role of PvEBP amplification towards Duffy-
negative erythrocyte invasion.
Evidences of Plasmodium vivax in Duffy‑negative 
individuals
The first indirect evidence of invasion of Duffy-negative 
reticulocytes by P. vivax came from travellers who pre-
sented with P. vivax infection after returning from coun-
tries in Africa where Duffy-negativity is at near fixation 
[54, 55]. Because P. vivax can remain as latent infections 
for months or even years before triggering a relapse 
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infection, it is difficult to confidently identify the source 
of P. vivax responsible for the blood stage infection in 
those individuals. In addition, there is yet insufficient 
data demonstrating the presence of P. vivax in Anopheles 
mosquitoes collected in areas where the majority of peo-
ple are Duffy-negative [39]. However, with the advent of 
sensitive molecular detection techniques, there has been 
a growing number of reports of P. vivax infections in 
Duffy-negative individuals.
The detection of P. vivax DNA by molecular and sero-
logical assays in a Duffy-negative individual’s blood 
sample could represent pre-erythrocytic stages of the 
parasites, independent of blood-stage infection [48]. 
Therefore, microscopic observation of P. vivax within 
Duffy-negative erythrocytes coupled by confirmation 
by genotyping has essentially proved Duffy-negative 
infection [50]. The first microscopic observation of P. 
vivax infection in a Duffy-negative erythrocyte was 
reported by Ryan et  al., in Kenya in [39] followed by a 
definitive evidence of a P. vivax infection within Duffy-
negative erythrocyte from patients in Madagascar [15]. 
Further experimental evidence on host susceptibility 
was obtained from a Nigerian who got infected with P. 
vivax through mosquito bite followed by the establish-
ment of P. vivax blood-stage infection [55], though the 
Duffy status of the infected individual was not confirmed. 
Future investigations of expanded anti-P. vivax antibody 
testings in Duffy-negative populations would reveal the 
extent of exposure and possible adaption of P. vivax for 
continuous transmission in these populations. Further-
more, P. vivax infections of Duffy-negative people have 
also been reported from the American continent using 
serological, molecular, and microscopic detection tools 
[56, 57]. While Duffy negativity is clearly no longer a bar-
rier against P. vivax infections, a recent study of P. vivax 
patients in the Brazilian Amazon region has shown that 
the null allele FY*02N.01 and weak allele FY*02W.01 were 
associated with low parasitaemia and low symptomatol-
ogy [58]. The presence of the polymorphic alleles could 
lead to a possible reduction in P. vivax adhesion by the 
reduction of the Duffy glycoprotein, as supported by 
earlier studies showing erythrocytes, expressing the 
FY*/FY*02N.01, have a significant reduction in para-
site adhesion when compared to erythrocytes express-
ing FY*02/FY*02 [59–61]. Therefore, the presence of 
FY*02N.01 and FY*02W.01 alleles may have an impact on 
the reduction of clinical manifestation in malaria, leading 
to the development of sub-clinical malaria.
Suggested mechanisms of Duffy‑negative reticulocyte 
invasion by Plasmodium vivax
Understanding of the mechanisms of RBC invasion 
by P. vivax in the absence of Duffy-positive receptor is 
imperative with respect to parasite epidemiology, pub-
lic health importance and elimination strategies against 
vivax malaria. To date, the question of whether P. vivax 
has recently evolved its strategies to infect Duffy-negative 
erythrocytes and utilized an alternative DARC-independ-
ent invasion pathway remains unclear. Characterizing 
this pathway is important in the development of inno-
vative strategies to prevent spread of P. vivax infections 
in Africa, and vaccine development. Unfortunately, the 
inherent challenge of culturing P. vivax in vitro has made 
studies targeting vivax malaria very difficult [62]. The 
involvement of putative parasite ligands in the invasion 
of Duffy-negative individuals has been described in a 
number of studies, but it remains unclear what specific 
receptor on the human erythrocyte is aiding the entry of 
P. vivax in Duffy-negative reticulocytes [50].
One suggested alternate invasion pathway of P. vivax is 
through the interaction between the human Duffy anti-
gen/receptor for chemokines (DARC, CD234) and the P. 
vivax EBP2, a new member of the DBP family [63]. Based 
on genome sequences of P. vivax field isolates and mon-
key-adapted strains, two possible invasion mechanisms 
have been proposed. The first mechanism is through 
duplication of the PvDBP gene observed in multiple 
P. vivax strains. The other is invasion through a novel 
PvEBP-driven pathway that contains conserved Duffy-
binding-like and C-terminal cysteine-rich domains that 
can be recognized by the Duffy receptor (Fig. 1) [64]. It 
is unclear what other possible host receptor(s) are rec-
ognized by PvEBP during the invasion process in Duffy-
negative individuals. However, panels of receptors on 
erythrocytes and reticulocytes as well as parasite ligands 
have been well described as the possible alternative path-
ways for Duffy-negative invasion [9].
One potential parasite ligands involved in Duffy-pos-
itive/Duffy-negative reticulocyte invasion is the family 
of P. vivax reticulocyte binding proteins (PvRBPs) [31]. 
Although PvRBPs ligands bind to erythrocytes, there are 
contradictory results regarding their specific binding to 
reticulocytes [9, 65]. Of the different PvRBPs previously 
examined, PvRBP1a and PvRBP2c bind to Duffy-negative 
erythrocytes [31]. However, PvRBP1a does not seem to 
be critical for P. vivax invasion of Duffy-positive cells 
[66]. The third member of the PvRBP family, PvRBP2b, 
was recently shown to be a key ligand involved in reticu-
locyte recognition and invasion through the transferrin 
receptor 1 (TfR1) [29]. However, the role of PvRBP1a 
and of PvRBP2b-TfR1 recognition of Duffy-negative red 
blood in P. vivax invasion of reticulocytes remain unclear. 
The membrane protein TfR1 is lost during red blood cell 
maturation and, therefore, absent in normocytes [67]. 
Theoretically, TfR1 should be present on the surface of 
both Duffy-positive and Duffy-negative reticulocytes. 
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The critical interaction between PvRBP2b and TfR1 
occurs upstream of the PvDBP-Duffy interaction, but is 
not independent of the latter [29]. Although the role of 
this interaction in Duffy-negative has not been assessed, 
it is proposed to play a key role in Duffy-independent 
invasion pathways [50]. PvRBP2b first binds to the TfR1 
present on reticulocytes before PvDBP engages with the 
Duffy protein, allowing entry of the merozoite in the red 
blood cell during invasion in Duffy-positives [50]. It has 
been shown that DARC knockout and TfR mutants indi-
vidually reduced P. vivax parasite invasion.
Plasmodium vivax merozoite surface protein-1 par-
alog (PvMSP1P) and P. vivax glycosylphosphatidylin-
ositol-anchored micronemal antigen (PvGAMA) were 
also shown to bind to both Duffy-positive and Duffy-
negative RBCs [68–70]. Taken together, this suggest that 
PvGAMA and PvMSP1P ligands could be involved in 
Duffy-independent reticulocyte invasion pathways even 
though their function is yet to be fully determined. Fur-
thermore, P. vivax erythrocyte-binding protein (PvEBP, 
also called PvDBP2) has also been shown to bind moder-
ately to Duffy-negative reticulocytes [64, 71].
It is as yet unclear whether a few Duffy molecules 
present on the surface of the erythrocyte enabling para-
sites with multiple PvDBP gene copies to invade the 
cell, or whether the invasion process of Duffy-negative 
reticulocytes could occur through alternate pathways by 
non-DBP ligands (PvEBP, PvMSP1P, or PvGAMA) [50]. 
Another plausible explanation for Duffy-negative inva-
sion is that the Duffy-negative phenotype may not be 
entirely a Duffy null and that the Duffy receptor may 
be expressed at a subtle level sufficient enough for low 
level invasion. The c.-67T>C mutation in GATA-1 tran-
scription factor has been confirmed in P. vivax-infected 
Duffy-negative individual [15]. This mutation is known 
to reduce the binding of the GATA-1 transcription fac-
tor and gene transcription. However, the reduced levels 
of RNA transcripts may still permit low expression and 
binding of the Duffy receptor protein with PvDBP. Thus, 
it is possible that Duffy-negative individuals could have 
been asymptomatic carriers of P. vivax for some time 
before symptoms emerged. These asymptomatic cases 
could have escaped the detection by current diagnostic 
tools and/or regimes in most African countries that pri-
marily target P. falciparum. Plasmodium vivax is now 
confirmed not to be completely absent from western and 
central Africa, though the dominance of Duffy-negative 
individuals in these regions has kept the prevalence of P. 
vivax low. Moreover, the presence of very low propor-
tion of Duffy-positive individuals could have minimized 
P. vivax transmission in these regions, though there is no 
evidence of direct transmission among Duffy-negative 
individuals and between Duffy-positive and Duffy-neg-
ative individuals. Lastly, the contribution of alternative 
hosts such as apes [72], the geographical range of P. vivax 
parasites [73], its red blood cell invasion protein reper-
toire [74], and the human and non-human primate hosts 
that are infected [75] cannot be neglected in facilitating 
transmission. Given that Duffy-negative people are not 
completely resistant to P. vivax blood stage malaria [11], 
new reservoirs of P. vivax within infected individuals 
must be considered [26].
Conclusion
Infection of Duffy-negative individuals by P. vivax 
remains an enigma for parasitology and evolution. Since 
most individuals of African origin are Duffy-negative and 
do not express the DARC antigen on the surface of their 
erythrocytes, it is unclear whether the high prevalence 
of Duffy-negative alleles in African populations results 
Fig. 1 Interaction between parasite ligands and reticulocyte receptors during invasion process of Duffy‑positive and Duffy‑negative cells 
by Plasmodium vivax (adapted from Popovici et al. [50]). A spectrum of ligands on the merozoite surface of the parasites that may bind to 
Duffy‑negative and Duffy‑positive reticulocytes are presented
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from P. vivax resistance selection [76] or there exists 
hidden transmission of P. vivax among Duffy-negative 
populations. The public health significance of P. vivax is 
increasingly apparent in Africa. Duffy-negative reticulo-
cyte infection by P. vivax highlights the risk of emergence 
and spread of vivax malaria in Africa where it was non-
existent before. Apart from the Horn of Africa, Mada-
gascar and Mauritania, P. vivax is grossly overlooked in 
many parts of the African continent. Given the low para-
sitaemia associated with P. vivax infections in Duffy-neg-
ative individuals, microscopy and RDTs are not sensitive 
enough to detect. Therefore, the contemporary epidemi-
ology of vivax malaria in Africa is vastly unknown [17]. 
This calls for sensitive molecular detection tools such 
as PCR for the diagnosis of low-density P. vivax infec-
tions and studies that further characterize genomic loci 
under selection in P. vivax isolates infecting Duffy-neg-
ative individuals. Future studies towards a better insight 
of erythrocyte invasion mechanism could be obtained 
by comparison of gene expression profiles of parasites 
infecting Duffy-negative and Duffy-positive people and 
identifying genes specifically up-regulated in Duffy-neg-
ativity infections. The evolution of P. vivax  strains able 
to infect RBCs not expressing Duffy antigen could have 
important implications for vaccine development. Increas-
ing efforts for continuous surveillance of P. vivax strains 
capable of invading red cell through Duffy-independent 
pathway is essential for designing P. vivax-specific vac-
cine candidates. A better understanding of the epidemi-
ology of P. vivax enables the design of P. vivax-specific 
control and elimination strategies. Given the presence 
of an ideal temperature, highly competent vectors for its 
transmission, and the apparent increase in the host range, 
P. vivax seems to expand to areas where it was non-exist-
ent in the past in Africa. It is imperative to consider how 
the growing evidence that P. vivax is not restricted to a 
Duffy-dependent invasion pathway is affecting the Afri-
can population at risk of vivax malaria.
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